Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD .
It may also improve local symptoms .
Until further evidence on the relative effectiveness of different lipid-lowering agents is available , use of a statin in people with PAD and a blood cholesterol level > /=3.5 mmol/litre is most indicated
BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease .
It may also reduce cardiovascular events and /or local disease progression in people with lower limb peripheral arterial disease ( PAD ) .
OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality , cardiovascular events and local disease progression in patients with PAD of the lower limb .
Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease.
BACKGROUND Patients with peripheral arterial disease ( PAD ) are at an increased risk of cardiovascular mortality and morbidity and thus are an excellent group in whom to evaluate the feasibility and the effect of an aggressive multifactorial intervention on atherosclerotic vascular disease risk factors . The Arterial Disease Multiple Intervention Trial ( ADMIT ) was design ed to determine the efficacy , safety , and compliance of an multifactorial therapy on selected atherosclerotic disease risk factors in patients with PAD . METHODS By a 2 x 2 x 2 factorial design , eligible participants ( N = 468 ) were r and omly assigned to low-dose warfarin , antioxidant vitamins , and niacin or its corresponding placebo , and followed up for 1 year . All participants were encouraged to use aspirin . Pravastatin was added to the drug regimen for those who needed to reduce LDL cholesterol to recommended levels . RESULTS Niacin increased HDL cholesterol levels by 30 % , with the majority of effect achieved at a dosage of 500 mg twice daily . Warfarin had an anticoagulant effect . The antioxidant vitamins result ed in a significant increase in vitamin E , C , and beta-carotene plasma levels . Overall , compliance was high and few adverse effects were reported . CONCLUSIONS ADMIT demonstrates that it is both feasible and safe to modify multiple atherosclerotic disease risk factors effectively with intensive combination therapy in patients with PAD
Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD .
It may also improve local symptoms .
Until further evidence on the relative effectiveness of different lipid-lowering agents is available , use of a statin in people with PAD and a blood cholesterol level > /=3.5 mmol/litre is most indicated
BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease .
It may also reduce cardiovascular events and /or local disease progression in people with lower limb peripheral arterial disease ( PAD ) .
OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality , cardiovascular events and local disease progression in patients with PAD of the lower limb .